Shopping Cart 0
Cart Subtotal
USD 0

Precipio Inc (TBIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Precipio Inc (Precipio), formerly Transgenomic Inc, is a developer and provider of diagnostic tools and services. The company advances personalized medicine for the detection and treatment of cancer, and inherited diseases through its molecular technologies and clinical and research services. It offers ICEme Kits, which finds applications for mutation specific, disease specific and gene specific panels. Precipio uses ICE COLD-PCR, a sensitivity platform technology, which enables adoption of personalized, precision medicine in cancer and other diseases. Transgenomic'S MX-ICP is an amplification technology that suppresses normal DNA and thereby enables the selective amplification of mutations. Its MX-ICP works on sample types that contain DNA, including tissue, blood, urine and saliva or sputum. It operates through its research and development facility located in Omaha, Nebraska, the US. Precipio is headquartered in Omaha, Nebraska, the US.

Precipio Inc (TBIO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Precipio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Precipio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Precipio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Precipio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Precipio Inc, Medical Devices Deals, 2012 to YTD 2018 10

Precipio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Precipio Inc, Pharmaceuticals & Healthcare, Deal Details 12

Asset Purchase 12

Transgenomic To Acquire Clinical Sample Biorepository Assets From Gene Logic For USD 0.3 Million 12

Partnerships 13

Transgenomic Enters Into Co-Marketing Agreement With PerkinElmer For Oncology Diagnostic Test Portfolio 13

Transgenomic Enters Into Co-Development Agreement With Amgen For IVD Test 14

Transgenomic Enters Into Co-Development Agreement With Medical College of Wisconsin 15

Licensing Agreements 16

LabCorp Enters into Licensing Agreement with Transgenomic 16

Transgenomic Expands Licensing Agreement with Exiqon 17

Equity Offering 18

Transgenomic Raises USD1.2 Million in First Tranche of Private Placement of Shares 18

Transgenomic to Raise up to USD3.5 Million in Public Offering of Shares 20

Transgenomic Raises up to USD2.2 Million in Private Placement of Preferred Stock and Warrant 21

Transgenomic to Raise USD3 Million in Private Placement 22

Transgenomic Raises USD7 Million in Public Offering of Shares and Warrants 23

Transgenomic Raises USD7 Million in Private Placement of Shares 25

Transgenomic Completes Private Placement Of Shares For USD8.3 Million 26

Transgenomic Completes Private Placement Of Shares For USD 19 Million 27

Debt Offering 28

Transgenomic Raises USD1.2 Million in Private Placement 28

Transgenomic Raises USD0.9 Million in Priavte Placement of Promissory Notes 29

Precipio Inc-Key Competitors 30

Precipio Inc-Key Employees 31

Precipio Inc-Locations And Subsidiaries 32

Head Office 32

Other Locations & Subsidiaries 32

Recent Developments 33

Financial Announcements 33

Jul 18, 2018: Precipio announces 213% year-over-year revenue growth in preliminary Q2-2018 results 33

Corporate Communications 34

Aug 09, 2018: Precipio Appoints New Board Member to Replace Departing Director 34

Legal and Regulatory 35

Mar 13, 2018: Precipio Settles Lawsuit with Crede Capital 35

Government and Public Interest 36

Apr 03, 2018: Important JAMA Article Underscores Superiority of Precipio's Liquid Biopsy Core Technology 36

Other Significant Developments 38

Apr 11, 2018: Precipio Launches ICE COLD-PCR Research Access Program for Cancer Centers 38

Appendix 40

Methodology 40

About GlobalData 40

Contact Us 40

Disclaimer 40


List Of Figure

List of Figures

Precipio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Precipio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Precipio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Precipio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Precipio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Precipio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Precipio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Precipio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Precipio Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Precipio Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Precipio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Precipio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Precipio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Precipio Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Precipio Inc, Medical Devices Deals, 2012 to YTD 2018 10

Precipio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Transgenomic To Acquire Clinical Sample Biorepository Assets From Gene Logic For USD 0.3 Million 12

Transgenomic Enters Into Co-Marketing Agreement With PerkinElmer For Oncology Diagnostic Test Portfolio 13

Transgenomic Enters Into Co-Development Agreement With Amgen For IVD Test 14

Transgenomic Enters Into Co-Development Agreement With Medical College of Wisconsin 15

LabCorp Enters into Licensing Agreement with Transgenomic 16

Transgenomic Expands Licensing Agreement with Exiqon 17

Transgenomic Raises USD1.2 Million in First Tranche of Private Placement of Shares 18

Transgenomic to Raise up to USD3.5 Million in Public Offering of Shares 20

Transgenomic Raises up to USD2.2 Million in Private Placement of Preferred Stock and Warrant 21

Transgenomic to Raise USD3 Million in Private Placement 22

Transgenomic Raises USD7 Million in Public Offering of Shares and Warrants 23

Transgenomic Raises USD7 Million in Private Placement of Shares 25

Transgenomic Completes Private Placement Of Shares For USD8.3 Million 26

Transgenomic Completes Private Placement Of Shares For USD 19 Million 27

Transgenomic Raises USD1.2 Million in Private Placement 28

Transgenomic Raises USD0.9 Million in Priavte Placement of Promissory Notes 29

Precipio Inc, Key Competitors 30

Precipio Inc, Key Employees 31

Precipio Inc, Other Locations 32

Precipio Inc, Subsidiaries 32

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Precipio Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.